GS 9256

Drug Profile

GS 9256

Alternative Names: GS-9256

Latest Information Update: 26 Jun 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Gilead Sciences
  • Class Antivirals
  • Mechanism of Action Hepatitis C protease inhibitors; Hepatitis C virus NS3 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Suspended Hepatitis C

Most Recent Events

  • 05 Sep 2011 Gilead terminates dosing of tegobuvir in patients receiving a four-drug regimen in a phase IIb trial of GS 9256
  • 01 Sep 2011 Pharmacodynamics data from early research in Hepatitis C presented at the 242nd American Chemical Society National Meeting (ACS-2011)
  • 18 Aug 2011 Gilead Sciences completes enrolment in its phase II trial for Hepatitis C in USA, Canada & European Union (NCT01225380)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top